Hematological and acute-phase responses to diet-induced obesity in IL-6 KO mice

Cytokine

Volumn 56, Issue 3, 2011, Pages 708-716

  Pini, Maria ^a   Rhodes, Davina H ^a   Fantuzzi, Giamila ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Acute phase response; Inflammation; Leukocytes; Obesity; Platelets

Indexed keywords

CERULOPLASMIN; HEPCIDIN; HEPCIDIN 1; HEPCIDIN 2; INTERLEUKIN 6; LIPOPOLYSACCHARIDE BINDING PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERUM AMYLOID A; SERUM AMYLOID A 1; THROMBOPOIETIN; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ABDOMINAL CAVITY INFLAMMATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SIZE; CONTROLLED STUDY; FAT INTAKE; HEMATOLOGICAL PARAMETERS; HEPATOMEGALY; HYPERLEPTINEMIA; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; LEUKOCYTOSIS; MALE; MEGAKARYOCYTE; MOUSE; NONHUMAN; OBESITY; PERITONEAL FLUID; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; WILD TYPE;

ACUTE-PHASE REACTION; ANIMALS; DIET; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-11; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OBESITY; SERUM AMYLOID A PROTEIN; THINNESS; THROMBOPOIETIN;

MUS;

EID: 81455154345     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.09.015     Document Type: Article

References (54)

1. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005, 115:911-919; quiz 920.
2. Wallenius V., Wallenius K., Ahren B., Rudling M., Carlsten H., Dickson S.L., et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002, 8:75-79.
3. Matthews V.B., Allen T.L., Risi S., Chan M.H.S., Henstridge D.C., Watson N., et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 2010, 53:2431-2441.
4. Di Gregorio G.B., Hensley L., Lu T., Ranganathan G., Kern P.A. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab 2004, 287:E182-E187.
5. Park E.J., Lee J.H., Yu G.Y., He G., Ali S.R., Holzer R.G., et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF alpha expression. Cell 2010, 140:197-208.
6. Ellingsgaard H., Ehses J.A., Hammar E.B., Van Lommel L., Quintens R., Martens G., et al. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci USA 2008, 105:13163-13168.
7. Wunderlich F.T., Ströhle P., Könner A.C., Gruber S., Tovar S., Brönneke H.S., et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab 2010, 12:237-249.
8. Suffredini A.F., Fantuzzi G., Badolato R., Oppenheim J.J., O'Grady N.P. New insights into the biology of the acute phase response. J Clin Immunol 1999, 19:203-214.
9. Bengmark S. Acute and "chronic" phase reaction-a mother of disease. Clin Nutr 2004, 23:1256-1266.
10. Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci 2007, 12:2957-2966.
11. Hua S., Song C., Geczy C.L., Freedman S.B., Witting P.K. A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis. Redox Rep 2009, 14:187-196.
12. Varma V., Yao-Borengasser A., Bodles A.M., Rasouli N., Phanavanh B., Nolen G.T., et al. Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance. Diabetes 2008, 57:432-439.
13. Ruiz A.G., Casafont F., Crespo J., Cayon A., Mayorga M., Estebanez A., et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007, 17:1374-1380.
14. Chua A.C., Graham R.M., Trinder D., Olynyk J.K. The regulation of cellular iron metabolism. Crit Rev Clin Lab Sci 2007, 44:413-459.
15. Herishanu Y., Rogowski O., Polliack A., Marilus R. Leukocytosis in obese individuals: possible link in patients with unexplained persistent neutrophilia. Eur J Haematol 2006, 76:516-520.
16. Nanji A.A., Freeman J.B. Relationship between body weight and total leukocyte count in morbid obesity. Am J Clin Pathol 1985, 84:346-347.
17. Samocha-Bonet D., Justo D., Rogowski O., Saar N., Abu-Abeid S., Shenkerman G., et al. Platelet counts and platelet activation markers in obese subjects. Mediators Inflamm 2008, 2008:834153.
18. Coban E., Ozdogan M., Yazicioglu G., Akcit F. The mean platelet volume in patients with obesity. Int J Clin Pract 2005, 59:981-982.
19. Coban E., Yilmaz A., Sari R. The effect of weight loss on the mean platelet volume in obese patients. Platelets 2007, 18:212-216.
20. Coban E., Bostan F., Ozdogan M. The mean platelet volume in subjects with impaired fasting glucose. Platelets 2006, 17:67-69.
21. Arslan N., Makay B. Mean platelet volume in obese adolescents with nonalcoholic fatty liver disease. J Pediatr Endocrinol Metab: JPEM 2010, 23:807-813.
22. Slavka G., Perkmann T., Haslacher H., Greisenegger S., Marsik C., Wagner O.F., et al. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arterioscler Thromb Vasc Biol 2011, 31:1215-1218.
23. Kishimoto T., Kishimoto N. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006, 2:619-626.
24. Riedemann N.C., Neff T.A., Guo R.F., Bernacki K.D., Laudes I.J., Sarma J.V., et al. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol 2003, 170:503-507.
25. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006, 116:1310-1316.
26. Matic G.B., Chapman E.S., Zaiss M., Rothe G., Schmitz G. Whole blood analysis of reticulated platelets: improvements of detection and assay stability. Cytometry 1998, 34:229-234.
27. Mathur A., Marine M., Lu D., Swartz-Basile D.A., Saxena R., Zyromski N.J., et al. Nonalcoholic fatty pancreas disease. HPB [Oxford] 2007, 9:312-318.
28. Kaser A., Brandacher G., Steurer W., Kaser S., Offner F., Zoller H., et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001, 98:2720-2725.
29. Sui X., Tsuji K., Ebihara Y., Tanaka R., Muraoka K., Yoshida M., et al. Soluble interleukin-6 (IL-6) receptor with IL-6 stimulates megakaryopoiesis from human CD34(+) cells through glycoprotein (gp)130 signaling. Blood 1999, 93:2525-2532.
30. Maury E., Ehala-Aleksejev K., Guiot Y., Detry R., Vandenhooft A., Brichard S.M. Adipokines oversecreted by omental adipose tissue in human obesity. Am J Physiol Endocrinol Metab 2007, 293:E656-E665.
31. Kaushansky K. Determinants of platelet number and regulation of thrombopoiesis. Hematol Am Soc Hematol Educ Program 2009, 147-152.
32. Tiedt R., Coers J., Ziegler S., Wiestner A., Hao-Shen H., Bornmann C., et al. Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood 2009, 113:1768-1777.
33. Ciurea S.O., Hoffman R. Cytokines for the treatment of thrombocytopenia. Semin Hematol 2007, 44:166-182.
34. Tzotzas T., Evangelou P., Kiortsis D.N. Obesity, weight loss and conditional cardiovascular risk factors. Obes Rev 2011, 12:e282-e289.
35. Nemeth E., Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006, 26:323-342.
36. Malchow S., Thaiss W., Janner N., Gewiese-Rabsch J., Garbers C., Yamamoto K., et al. Essential role of neutrophil mobilization in concanavalin A-induced hepatitis is based on classic IL-6 signaling but not on IL-6 trans signaling. Biochim Biophys Acta 2011, 1812:290-301.
37. Gomez C.R., Nomellini V., Baila H., Oshima K., Kovacs E.K. Comparison of the effects of aging and IL-6 on the hepatic inflammatory response in two models of systemic injury: scald injury versus i.p. LPS administration. Shock 2009, 31:178-184.
38. Gainsford T., Nandurkar H., Metcalf D., Robb L., Begley C.G., Alexander W.S. The residual megakaryocyte and platelet production in c-mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor. Blood 2000, 95:528-534.
39. Burmester H., Wolber E.M., Freitag P., Fandrey J., Jelkmann W. Thrombopoietin production in wild-type and interleukin-6 knockout mice with acute inflammation. J Interferon Cytokine Res 2005, 25:407-413.
40. Deutsch V.R., Tomer A. Megakaryocyte development and platelet production. Br J Haematol 2006, 134:453-466.
41. Cepeda-Lopez A.C., Aeberli I., Zimmermann M.B. Does obesity increase risk for iron deficiency? A review of the literature and the potential mechanisms. Int J Vitam Nutr Res 2010, 80:263-270.
42. Rivera S., Ganz T. Animal models of anemia of inflammation. Semin Hematol 2009, 46:351-357.
43. Schmitt A., Guichard J., Masse J.M., Debili N., Cramer E.M. Of mice and men: comparison of the ultrastructure of megakaryocytes and platelets. Exp Hematol 2001, 29:1295-1302.
44. Fattori E., Cappelletti M., Costa P., Sellitto C., Cantoni L., Carelli M., et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994, 180:1243-1250.
45. Gamble L., Bagby G.J., Quinton L.J., Happel K.I., Mizgerd J.P., Zhang P., et al. The systemic and pulmonary LPS binding protein response to intratracheal lipopolysaccharide. Shock 2009, 31:212-217.
46. Naugler W.E., Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008, 14:109-119.
47. Manco M., Putignani L., Bottazzo G.F. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 2010, 31:817-844.
48. Cignarelli M., DePergola G., Picca G., Sciaraffia M., Pannacciulli N., Tarallo M., et al. Relationship of obesity and body fat distribution with ceruloplasmin serum levels. Int J Obes Relat Metab Disord 1996, 20:809-813.
49. Kim O.Y., Shin M.J., Moon J., Chung J.H. Plasma ceruloplasmin as a biomarker for obesity: a proteomic approach. Clin Biochem 2011, 44:351-356.
50. Tussing-Humphreys L.M., Nemeth E., Fantuzzi G., Freels S., Holterman A.X., Galvani C., et al. Decreased serum hepcidin and improved functional iron status 6 months after restrictive bariatric surgery. Obesity [Silver Spring] 2010, 18:2010-2016.
51. Truksa J., Lee P., Beutler E. The role of STAT, AP-1, E-box and TIEG motifs in the regulation of hepcidin by IL-6 and BMP-9: lessons from human HAMP and murine Hamp1 and Hamp2 gene promoters. Blood Cells Mol Dis 2007, 39:255-262.
52. Lou D.Q., Nicolas G., Lesbordes J.C., Viatte L., Grimber G., Szajnert M.F., et al. Functional differences between hepcidin 1 and 2 in transgenic mice. Blood 2004, 103:2816-2821.
53. Ilyin G., Courselaud B., Troadec M.B., Pigeon C., Alizadeh M., Leroyer P., et al. Comparative analysis of mouse hepcidin 1 and 2 genes: evidence for different patterns of expression and co-inducibility during iron overload. FEBS Lett 2003, 542:22-26.
54. Ahmed M., Neville M.J., Edelmann M.J., Kessler B.M., Karpe F. Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity 2009, 18:27-34.